These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 21035472

  • 21. Differential involvement of cyclase- versus non-cyclase-coupled D1-like dopamine receptors in orofacial movement topography in mice: studies with SKF 83822.
    Makihara Y, Okuda Y, Kawada C, Matsumoto M, Waddington JL, Koshikawa N, Tomiyama K.
    Neurosci Lett; 2007 Mar 19; 415(1):6-10. PubMed ID: 17234342
    [Abstract] [Full Text] [Related]

  • 22. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
    Depoortère R, Bardin L, Rodrigues M, Abrial E, Aliaga M, Newman-Tancredi A.
    Behav Pharmacol; 2009 Jul 19; 20(4):303-11. PubMed ID: 19584712
    [Abstract] [Full Text] [Related]

  • 23. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
    Maggio R, Scarselli M, Novi F, Millan MJ, Corsini GU.
    J Neurochem; 2003 Nov 19; 87(3):631-41. PubMed ID: 14535946
    [Abstract] [Full Text] [Related]

  • 24. A vehicle injection into the right core of the nucleus accumbens both reverses the region-specificity and alters the type of contralateral turning elicited by unilateral stimulation of dopamine D2/D3 and D1 receptors in the left core of the nucleus accumbens.
    Ikeda H, Kotani A, Koshikawa N, Cools AR.
    Eur J Pharmacol; 2007 Dec 22; 577(1-3):64-70. PubMed ID: 17884038
    [Abstract] [Full Text] [Related]

  • 25. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    J Pharmacol Exp Ther; 1997 Nov 22; 283(2):794-9. PubMed ID: 9353400
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Effects of hemantane on the main subtypes of dopamine receptors in the rat striatum ex vivo].
    Abaimov DA, Zimin IA, Kovalev GI.
    Eksp Klin Farmakol; 2008 Nov 22; 71(1):18-21. PubMed ID: 18365481
    [Abstract] [Full Text] [Related]

  • 32. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.
    Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT.
    J Pharmacol Exp Ther; 2001 Feb 22; 296(2):338-44. PubMed ID: 11160615
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
    Seeman P.
    Synapse; 2015 Apr 22; 69(4):183-9. PubMed ID: 25645960
    [Abstract] [Full Text] [Related]

  • 35. Dysbindin-1 modifies signaling and cellular localization of recombinant, human D₃ and D₂ receptors.
    Schmieg N, Rocchi C, Romeo S, Maggio R, Millan MJ, Mannoury la Cour C.
    J Neurochem; 2016 Mar 22; 136(5):1037-51. PubMed ID: 26685100
    [Abstract] [Full Text] [Related]

  • 36. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ.
    J Pharmacol Exp Ther; 1997 Jul 22; 282(1):181-91. PubMed ID: 9223553
    [Abstract] [Full Text] [Related]

  • 37. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW.
    J Pharmacol Exp Ther; 1995 Dec 22; 275(3):1355-66. PubMed ID: 8531103
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR, Hu XT, Galloway MP, White FJ.
    Synapse; 1989 Dec 22; 4(4):327-46. PubMed ID: 2532422
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, Hashida H, Kubo S, Suzuki M, Nanri K, Matsumura M, Murakami H, Hattori N, Tokyo Parkinson's Disease Study Group.
    Intern Med; 2013 Dec 22; 52(3):325-32. PubMed ID: 23370739
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.